相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association of insurance with cancer care utilization and outcomes
Elizabeth Ward et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Will targeted therapy hold its promise? An evidence-based review
David Murdoch et al.
CURRENT OPINION IN ONCOLOGY (2008)
Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005)
Amy Y. Chen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Insurance status and stage of cancer at diagnosis among women with breast cancer
Michael T. Halpern et al.
CANCER (2007)
Outlook - Development trends for monoclonal antibody cancer therapeutics
Janice M. Reichert et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
Allison W. Kurian et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
N. Starling et al.
BRITISH JOURNAL OF CANCER (2007)
Cytokine-based immunotherapy for advanced kidney cancer: Past results and future perspectives in the era of molecularly targeted agents
Camillo Porta et al.
THESCIENTIFICWORLDJOURNAL (2007)
The market for follow-on biologics: How will it evolve?
Henry Grabowski et al.
HEALTH AFFAIRS (2006)
Insurers' strategies for managing the use and cost of biopharmaceuticals
James C. Robinson
HEALTH AFFAIRS (2006)
'Follow-on biologics': Ensuring continued innovation in the biotechnology industry
BS Manheim et al.
HEALTH AFFAIRS (2006)
The roles of teaching hospitals, insurance status, and race/ethnicity in receipt of adjuvant therapy for regional-stage breast cancer in Florida
LC Richardson et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2006)
Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
FF Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma
JC Hornberger et al.
CANCER (2005)
Overview of monoclonal antibodies in cancer therapy: present and promise
M Stern et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Monoclonal antibody therapy of cancer
GP Adams et al.
NATURE BIOTECHNOLOGY (2005)
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
